What Makes This a Once-in-a-Decade Risk/Reward Profile?

Final 6 Days, Invest Before the Raise Closes August 27 at $3.00/Share.

Because moonshots are only worth taking if the math actually makes sense.

Every startup loves to claim they’re a “once-in-a-decade opportunity.” Usually, that’s code for: “We haven’t proven anything yet, but trust us, the vibes are immaculate.”

Cytonics is different.

Because the vibes are backed by:

• Real biology
• 25 issued patents
• Patient data
• $25M+ raised
• Phase 1 completed
• And the science is now peer-reviewed and independently validated

And with only 6 days left until the Reg A+ round closes on August 27 at 11:59 PM, this is the final window to invest at $3.00/share before future raises at potentially higher valuations.


First, Let’s Talk About The Risk (Because It’s Biotech)

Yes, biotech is risky. Always has been.

Things that can go wrong:

• Clinical trials miss endpoints
• Regulatory hurdles slow momentum
• Markets tighten
• Biology surprises you (and not in the fun way)

But in this case, the real question isn’t “Is there risk?” It’s: What are you getting in return for taking it?


Now? The Reward

Here’s what Cytonics already has in place:

• A clinical-stage drug candidate: CYT-108
• Phase 1 trial completed with zero drug-related adverse events
• Preclinical data showing up to 87% cartilage protection and >60% reduction in joint membrane inflammation
• Independent 3rd-party research showing cartilage regeneration potential
• A validated biologic platform with 25 patents
• Over 10,000 patients treated with the first-gen A2M-based therapy
• $25M+ raised from 7,000+ investors
• No venture capital, no liquidation preferences, no institutional control
• And now… a clear path to Phase 2, biotech’s single most value-driving milestone.

What Happens If They Succeed?

Let’s run the math:

• Addressable market = $393 billion
• Zero approved disease-modifying OA drugs
• CYT-108 could become the first of its kind
• Patent protection through the 2030s and beyond
• Potential applications across multiple protease-driven diseases: melanoma, COPD, ARDS, chronic wounds

This isn’t a new cream or a next-gen painkiller; it’s a platform play,11:59 PM, and it could be the TNF-inhibitor moment for osteoarthritis.

(Fun fact: Humira, the TNF-alpha inhibitor for RA, became the best-selling drug of all time, over $200B in lifetime revenue.)

Where Are We In The Cycle?

• Preclinical? Already done
• Phase 1? Completed
• Phase 2? Starting soon
• Widely known by Big Pharma? Not yet…

That makes this moment the sweet spot: The upside is still on the table, and the risk has already been shaved down. But it won’t last.


Just 6 Days Left To Join at $3.00/Share

Own shares in a platform-stage biotech.

Final Countdown To Invest

Invest today, raise closes August 27 at 11:59 PM.